Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00312130 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes
A Phase 3 study of PreDiabetes, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00312130: Completed Phase 3 study of PreDiabetes, sponsored by Novartis.
NCT00312130 is a Phase 3 study of PreDiabetes that has completed, run by Novartis. The registered enrollment target is 20 participants, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00312130, a Phase 3 study of PreDiabetes, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an exploratory study to assess whether vildagliptin, an unapproved drug, can increase insulin secretion in subjects with pre-diabetes who have a defect in the insulin response and elevated levels of fasting glucose.
Conditions Studied
Interventions
- DRUG Vildagliptin
Study Locations (1)
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
What the finished NCT00312130 record still lists
NCT00312130 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (97% lower).
The record links to 1 condition, with PreDiabetes appearing as the primary indexed condition, and to 1 intervention - of which Vildagliptin is the first listed.
NCT00312130 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT00312130 about?
NCT00312130 is a clinical study titled "A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes". This is an exploratory study to assess whether vildagliptin, an unapproved drug, can increase insulin secretion in subjects with pre-diabetes who have a defect in the insulin response and elevated levels of fasting glucose.
What is the current status of trial NCT00312130?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2005-04. Estimated completion is 2006-11.
What conditions does trial NCT00312130 study?
This clinical trial studies the following conditions: PreDiabetes.
What interventions are being tested in trial NCT00312130?
The interventions under investigation include: Vildagliptin (DRUG).
Who is sponsoring clinical trial NCT00312130?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00312130 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PreDiabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00312130's enrollment target sits among peer trials
20 133rd of 149 higher than 10 of 149 other PreDiabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other PreDiabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Role of Islet GLP-1 in the Pathogenesis of Prediabetes
RECRUITING · Phase 2
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention
RECRUITING · NA
-
Diabetes Clinical Decision Support
RECRUITING · NA
-
Glucose Variability and Cognition in Prediabetes
RECRUITING
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia